Moleculin Biotech (NASDAQ:MBRX) reported quarterly earnings results on August 14, 2026 that exceeded analyst expectations.
At publication ·
Moleculin Biotech (NASDAQ:MBRX) · earnings beat
At a glance
Moleculin Biotech (NASDAQ:MBRX) reported quarterly earnings results on August 14, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-1.40, beating the consensus estimate of $-1.55 by $0.15 per share. Revenue came in at , meeting the estimate of .
Moleculin Biotech's stock moved following the earnings release. The stock currently trades at $0.61 with a market capitalization of $6.0M.
Moleculin Biotech's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Moleculin Biotech should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q2 (Aug 2026) | $-1.40 | $-1.55 | +9.7% |
| Q1 (May 2026) | $-3.54 | $-1.67 | -112.0% |
| Q4 (Mar 2026) | $-26.06 | $-6.77 | -284.9% |
| Q3 (Sep 2025) | $-17.00 | $-4.97 | -241.9% |
Related Tools: Earnings Calendar | View MBRX Stock Page
Check the latest earnings dates on our MBRX earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our MBRX earnings page.
Current market data
NASDAQ · MBRX
$0.61
Up: +$0.04 · +7.16%
Live quote updated
Keep reading
earnings ·
sec_filing ·
sec_filing ·
sec_filing ·
